Publications by authors named "Martin Bexon"

Claim this Profile
A
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M Kranz, Martin Bexon

Nature· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Mohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, Glenn J Hanna, Douglas E Laux, Alice S Bexon, Martin F Bexon

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.
Nicola L Brice, Mark Carlton, David H Margolin, Martin Bexon, Kim L Matthews

EClinicalMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
John H Sampson, Achal Singh Achrol, Manish K Aghi, Krystof Bankiewicz, Martin Bexon

Neuro Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Benjamin M Ellingson, John Sampson, Achal Singh Achrol, Manish K Aghi, Krystof Bankiewicz, Martin Bexon

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Ugur Sahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M Kranz, Martin Bexon

Nature· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.
Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M Kranz, Martin Bexon

Nature· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.
Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M Kranz, Martin Bexon

Nature· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
Michael A Tortorici, James A Rogers, Oliver Vit, Martin Bexon, Robert A Sandhaus

Br J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.
Stephen Jolles, Michael Borte, Robert P Nelson, Mikhail Rojavin, Martin Bexon

Clin Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Hirokazu Kanegane, Kohsuke Imai, Masafumi Yamada, Hidetoshi Takada, Tadashi Ariga, Martin Bexon

J Clin Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.
Cornelia B Landersdorfer, Martin Bexon, Jonathan Edelman, Mikhail Rojavin, Carl M J Kirkpatrick

Postgrad Med· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency.
Elie Haddad, Melvin Berger, Edward C Y Wang, Christopher A Jones, Martin Bexon

J Clin Immunol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis